Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 5
2001 16
2002 28
2003 82
2004 126
2005 242
2006 318
2007 404
2008 485
2009 568
2010 640
2011 674
2012 797
2013 799
2014 807
2015 816
2016 781
2017 757
2018 725
2019 765
2020 824
2021 775
2022 697
2023 634
2024 223

Text availability

Article attribute

Article type

Publication date

Search Results

11,419 results

Results by year

Filters applied: . Clear all
Page 1
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
Yamamoto S, Egashira N. Yamamoto S, et al. Int J Mol Sci. 2021 Jan 17;22(2):888. doi: 10.3390/ijms22020888. Int J Mol Sci. 2021. PMID: 33477371 Free PMC article. Review.
Bortezomib, a first-generation proteasome inhibitor widely used in chemotherapy for hematologic malignancy, has effective anti-cancer activity but often causes severe peripheral neuropathy. Although bortezomib-induced peripheral neuropathy (BIPN) is a dose-limiting …
Bortezomib, a first-generation proteasome inhibitor widely used in chemotherapy for hematologic malignancy, has effective anti-cancer …
Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.
Tan CRC, Abdul-Majeed S, Cael B, Barta SK. Tan CRC, et al. Clin Pharmacokinet. 2019 Feb;58(2):157-168. doi: 10.1007/s40262-018-0679-9. Clin Pharmacokinet. 2019. PMID: 29802543 Review.
Bortezomib is available for subcutaneous and intravenous administration. ...In addition, we discuss the clinical efficacy and safety of bortezomib....
Bortezomib is available for subcutaneous and intravenous administration. ...In addition, we discuss the clinical efficacy and safety …
Bortezomib for the treatment of multiple myeloma.
Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Scott K, et al. Cochrane Database Syst Rev. 2016 Apr 20;4(4):CD010816. doi: 10.1002/14651858.CD010816.pub2. Cochrane Database Syst Rev. 2016. PMID: 27096326 Free PMC article. Review.
SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared i) bortezomib versus no bortezomib with the same background therapy in each arm; ii) bortezomib versus no bortezomib with different background therapy in each arm or comp …
SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared i) bortezomib versus no bortezomib with the …
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min CK, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, Spencer A. Mateos MV, et al. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509-518. doi: 10.1016/j.clml.2019.09.623. Epub 2019 Oct 9. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32482541 Free article. Clinical Trial.
BACKGROUND: In the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. ...PATIENTS AND METHODS: Eligible patients had received 1 line of treatment an …
BACKGROUND: In the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-V …
Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.
Syed YY. Syed YY. Target Oncol. 2023 Mar;18(2):303-310. doi: 10.1007/s11523-022-00945-3. Epub 2023 Jan 9. Target Oncol. 2023. PMID: 36622630 Review.
Selinexor-bortezomib-dexamethasone had a generally manageable tolerability profile and an acceptable safety profile in BOSTON, with a lower incidence of peripheral neuropathy (a bortezomib-induced toxicity) compared with bortezomib-dexamethasone. ...Selinexor …
Selinexor-bortezomib-dexamethasone had a generally manageable tolerability profile and an acceptable safety profile in BOSTON, with a …
The safety of bortezomib for the treatment of multiple myeloma.
Cengiz Seval G, Beksac M. Cengiz Seval G, et al. Expert Opin Drug Saf. 2018 Sep;17(9):953-962. doi: 10.1080/14740338.2018.1513487. Epub 2018 Aug 30. Expert Opin Drug Saf. 2018. PMID: 30118610 Review.
Bortezomib can be administered in the outpatient setting with manageable toxicities. ...This review gives an overview of the critical role of the bortezomib in multiple myeloma and provides a comprehensive summary of key clinical benefit and safety data with the …
Bortezomib can be administered in the outpatient setting with manageable toxicities. ...This review gives an overview of the critical …
Bortezomib in kidney transplantation.
Shah N, Meouchy J, Qazi Y. Shah N, et al. Curr Opin Organ Transplant. 2015 Dec;20(6):652-6. doi: 10.1097/MOT.0000000000000252. Curr Opin Organ Transplant. 2015. PMID: 26536428 Review.
RECENT FINDINGS: Several studies have analyzed bortezomib alone and in comparison to more traditional immunosuppressive agents during the last 2 years. If administered prior to transplant or soon thereafter, bortezomib appears to lower donor-specific antibody levels …
RECENT FINDINGS: Several studies have analyzed bortezomib alone and in comparison to more traditional immunosuppressive agents during …
Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Mahmoudian M, Valizadeh H, Löbenberg R, Zakeri-Milani P. Mahmoudian M, et al. J Microencapsul. 2021 May;38(3):192-202. doi: 10.1080/02652048.2021.1876175. Epub 2021 Feb 2. J Microencapsul. 2021. PMID: 33530812 Review.
AIM: Nano drug delivery systems can provide the opportunity to reduce side effects and improve the therapeutic aspect of a variety of drugs. Bortezomib (BTZ) is a proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma. ...
AIM: Nano drug delivery systems can provide the opportunity to reduce side effects and improve the therapeutic aspect of a variety of drugs. …
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.
Robak P, Robak T. Robak P, et al. Drugs R D. 2019 Jun;19(2):73-92. doi: 10.1007/s40268-019-0269-9. Drugs R D. 2019. PMID: 30993606 Free PMC article. Review.
Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. ...In 2006, bortezomib was approved for the treatment of refractory/relapsed mantle cell lymphom …
Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degrada …
Bortezomib in the treatment of mantle cell lymphoma.
Robak T. Robak T. Future Oncol. 2015;11(20):2807-18. doi: 10.2217/fon.15.191. Epub 2015 Sep 8. Future Oncol. 2015. PMID: 26347482 Review.
Single-agent bortezomib has demonstrated clinical efficacy in relapsed and refractory MCL with objective response in up to 47% of the patients. ...This review explores bortezomib as therapy in patients with MCL....
Single-agent bortezomib has demonstrated clinical efficacy in relapsed and refractory MCL with objective response in up to 47% of the …
11,419 results
You have reached the last available page of results. Please see the User Guide for more information.